Anti-epileptic Zebinix receives EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has granted a marketing authorisation for the novel once-daily anti-epileptic Zebinix (eslicarbazepine acetate) as an adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation, Bial and Eisai announced today.